Myriam Amsallem1, Andrew J Sweatt2, Marie C Aymami2, Tatiana Kuznetsova2, Mona Selej2, HongQuan Lu2, Olaf Mercier2, Elie Fadel2, Ingela Schnittger2, Michael V McConnell2, Marlene Rabinovitch2, Roham T Zamanian2, Francois Haddad2. 1. From the Division of Cardiovascular Medicine (M.A., M.C.A., M.S., H.L., I.S., M.V.M., F.H.), Cardiovascular Institute (M.A., M.C.A., H.L., I.S., M.V.M., F.H.), Division of Pulmonary and Critical Care Medicine (A.J.S., R.T.Z.), Vera Moulton Wall Center at Stanford (M.R., R.T.Z., F.H.), and Division of Pediatrics (M.R.), Stanford University School of Medicine, CA; Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (T.K.); and Division of Cardiothoracic Surgery, Marie Lannelongue Hospital, Le Plessis Robinson, France (O.M., E.F., M.A.). mamsallem@stanford.edu. 2. From the Division of Cardiovascular Medicine (M.A., M.C.A., M.S., H.L., I.S., M.V.M., F.H.), Cardiovascular Institute (M.A., M.C.A., H.L., I.S., M.V.M., F.H.), Division of Pulmonary and Critical Care Medicine (A.J.S., R.T.Z.), Vera Moulton Wall Center at Stanford (M.R., R.T.Z., F.H.), and Division of Pediatrics (M.R.), Stanford University School of Medicine, CA; Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (T.K.); and Division of Cardiothoracic Surgery, Marie Lannelongue Hospital, Le Plessis Robinson, France (O.M., E.F., M.A.).
Abstract
BACKGROUND: Right ventricular (RV) end-systolic dimensions provide information on both size and function. We investigated whether an internally scaled index of end-systolic dimension is incremental to well-validated prognostic scores in pulmonary arterial hypertension. METHODS AND RESULTS: From 2005 to 2014, 228 patients with pulmonary arterial hypertension were prospectively enrolled. RV end-systolic remodeling index (RVESRI) was defined by lateral length divided by septal height. The incremental values of RV free wall longitudinal strain and RVESRI to risk scores were determined. Mean age was 49±14 years, 78% were female, 33% had connective tissue disease, 52% were in New York Heart Association class ≥III, and mean pulmonary vascular resistance was 11.2±6.4 WU. RVESRI and right atrial area were strongly connected to the other right heart metrics. Three zones of adaptation (adapted, maladapted, and severely maladapted) were identified based on the RVESRI to RV systolic pressure relationship. During a mean follow-up of 3.9±2.4 years, the primary end point of death, transplant, or admission for heart failure was reached in 88 patients. RVESRI was incremental to risk prediction scores in pulmonary arterial hypertension, including the Registry to Evaluate Early and Long-Term PAH Disease Management score, the Pulmonary Hypertension Connection equation, and the Mayo Clinic model. Using multivariable analysis, New York Heart Association class III/IV, RVESRI, and log NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) were retained (χ2, 62.2; P<0.0001). Changes in RVESRI at 1 year (n=203) were predictive of outcome; patients initiated on prostanoid therapy showed the greatest improvement in RVESRI. Among right heart metrics, RVESRI demonstrated the best test-retest characteristics. CONCLUSIONS: RVESRI is a simple reproducible prognostic marker in patients with pulmonary arterial hypertension.
BACKGROUND: Right ventricular (RV) end-systolic dimensions provide information on both size and function. We investigated whether an internally scaled index of end-systolic dimension is incremental to well-validated prognostic scores in pulmonary arterial hypertension. METHODS AND RESULTS: From 2005 to 2014, 228 patients with pulmonary arterial hypertension were prospectively enrolled. RV end-systolic remodeling index (RVESRI) was defined by lateral length divided by septal height. The incremental values of RV free wall longitudinal strain and RVESRI to risk scores were determined. Mean age was 49±14 years, 78% were female, 33% had connective tissue disease, 52% were in New York Heart Association class ≥III, and mean pulmonary vascular resistance was 11.2±6.4 WU. RVESRI and right atrial area were strongly connected to the other right heart metrics. Three zones of adaptation (adapted, maladapted, and severely maladapted) were identified based on the RVESRI to RV systolic pressure relationship. During a mean follow-up of 3.9±2.4 years, the primary end point of death, transplant, or admission for heart failure was reached in 88 patients. RVESRI was incremental to risk prediction scores in pulmonary arterial hypertension, including the Registry to Evaluate Early and Long-Term PAH Disease Management score, the Pulmonary Hypertension Connection equation, and the Mayo Clinic model. Using multivariable analysis, New York Heart Association class III/IV, RVESRI, and log NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) were retained (χ2, 62.2; P<0.0001). Changes in RVESRI at 1 year (n=203) were predictive of outcome; patients initiated on prostanoid therapy showed the greatest improvement in RVESRI. Among right heart metrics, RVESRI demonstrated the best test-retest characteristics. CONCLUSIONS: RVESRI is a simple reproducible prognostic marker in patients with pulmonary arterial hypertension.
Authors: Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller Journal: J Am Soc Echocardiogr Date: 2010-07 Impact factor: 5.251
Authors: Anton Vonk-Noordegraaf; François Haddad; Kelly M Chin; Paul R Forfia; Steven M Kawut; Joost Lumens; Robert Naeije; John Newman; Ronald J Oudiz; Steve Provencher; Adam Torbicki; Norbert F Voelkel; Paul M Hassoun Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Mariëlle C van de Veerdonk; Taco Kind; J Tim Marcus; Gert-Jan Mauritz; Martijn W Heymans; Harm-Jan Bogaard; Anco Boonstra; Koen M J Marques; Nico Westerhof; Anton Vonk-Noordegraaf Journal: J Am Coll Cardiol Date: 2011-12-06 Impact factor: 24.094
Authors: M Humbert; O Sitbon; A Yaïci; D Montani; D S O'Callaghan; X Jaïs; F Parent; L Savale; D Natali; S Günther; A Chaouat; F Chabot; J-F Cordier; G Habib; V Gressin; Z-C Jing; R Souza; G Simonneau Journal: Eur Respir J Date: 2010-06-18 Impact factor: 16.671
Authors: Mariëlle C van de Veerdonk; J Tim Marcus; Nico Westerhof; Frances S de Man; Anco Boonstra; Martijn W Heymans; Harm-Jan Bogaard; Anton Vonk Noordegraaf Journal: Chest Date: 2015-04 Impact factor: 9.410
Authors: François Haddad; Onno A Spruijt; Andre Y Denault; Olaf Mercier; Nathan Brunner; David Furman; Elie Fadel; Harm J Bogaard; Ingela Schnittger; Bojan Vrtovec; Joseph C Wu; Vinicio de Jesus Perez; Anton Vonk-Noordegraaf; Roham T Zamanian Journal: JACC Cardiovasc Imaging Date: 2015-05-14
Authors: S Ghio; F Recusani; C Klersy; R Sebastiani; M L Laudisa; C Campana; A Gavazzi; L Tavazzi Journal: Am J Cardiol Date: 2000-04-01 Impact factor: 2.778
Authors: C Sciaccaluga; F D'Ascenzi; G E Mandoli; L Rizzo; N Sisti; C Carrucola; P Cameli; E Bigio; S Mondillo; M Cameli Journal: Curr Heart Fail Rep Date: 2020-04
Authors: Johannes Krämer; Felix Kreuzer; Michael Kaestner; Peter Bride; Fabian von Scheidt; Jannos Siaplaouras; Heiner Latus; Dietmar Schranz; Christian Apitz Journal: Pediatr Cardiol Date: 2018-03-14 Impact factor: 1.655
Authors: Antoine Vieillard-Baron; R Naeije; F Haddad; H J Bogaard; T M Bull; N Fletcher; T Lahm; S Magder; S Orde; G Schmidt; M R Pinsky Journal: Intensive Care Med Date: 2018-05-09 Impact factor: 17.440
Authors: Maurice Beghetti; Rolf M F Berger; Damien Bonnet; Simon Grill; Catherine Lesage; Jean-Christophe Lemarie; D Dunbar Ivy Journal: Front Pediatr Date: 2021-06-16 Impact factor: 3.418